FOLD Amicus Therapeutics, Inc. Stock Quote

FOLD [NASD]

Index	-	P/E	-	EPS (ttm)	-0.97	Insider Own	1.10%	Shs Outstand	264.37M	Perf Week	5.33%
Market Cap	2.48B	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-6.68%	Shs Float	241.80M	Perf Month	-3.63%
Income	-253.60M	PEG	-	EPS next Q	-0.22	Inst Own	-	Short Float	12.27%	Perf Quarter	-5.59%
Sales	266.80M	P/S	9.30	EPS this Y	27.90%	Inst Trans	0.30%	Short Ratio	11.99	Perf Half Y	-50.87%
Book/sh	0.95	P/B	9.78	EPS next Y	38.40%	ROA	-30.70%	Target Price	-	Perf Year	-36.72%
Cash/sh	1.56	P/C	5.95	EPS next 5Y	-1.00%	ROE	-83.20%	52W Range	8.60 - 25.39	Perf YTD	-59.77%
Dividend	-	P/FCF	-	EPS past 5Y	2.30%	ROI	-38.00%	52W High	-63.41%	Beta	1.07
Dividend %	-	Quick Ratio	4.90	Sales past 5Y	-	Gross Margin	88.40%	52W Low	8.02%	ATR	0.36
Employees	483	Current Ratio	5.00	Sales Q/Q	9.80%	Oper. Margin	-85.90%	RSI (14)	49.10	Volatility	3.42% 4.13%
Optionable	Yes	Debt/Eq	1.55	EPS Q/Q	28.20%	Profit Margin	-95.10%	Rel Volume	0.67	Prev Close	9.33
Shortable	Yes	LT Debt/Eq	1.55	Earnings	Aug 05 BMO	Payout	-	Avg Volume	2.47M	Price	9.29
Recom	2.60	SMA20	0.79%	SMA50	-2.98%	SMA200	-36.71%	Volume	1,663,916	Change	-0.43%

Jul-19-21

Resumed

BTIG Research

Buy

$15

May-27-21

Initiated

Needham

Hold

May-21-21

Initiated

UBS

Buy

$16

Apr-14-21

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$17

Mar-02-21

Initiated

Stifel

Hold

$13

Feb-12-21

Downgrade

JP Morgan

Overweight → Neutral

$19

Feb-12-21

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$30 → $17

Dec-28-20

Resumed

Cantor Fitzgerald

Overweight

$20 → $30

Dec-10-20

Downgrade

Citigroup

Buy → Neutral

$20 → $27

Nov-11-20

Initiated

Berenberg

Hold

Jun-17-20

Initiated

BTIG Research

Buy

$19

Feb-04-20

Resumed

Cantor Fitzgerald

Overweight

$19 → $20

Nov-12-19

Reiterated

H.C. Wainwright

Buy

$18 → $20

Jun-17-19

Initiated

H.C. Wainwright

Buy

$18

Jun-05-19

Reiterated

Cantor Fitzgerald

Overweight

$20 → $19

Apr-05-19

Initiated

Janney

Buy

Jan-30-19

Initiated

Cantor Fitzgerald

Overweight

$20

Oct-29-18

Initiated

Citigroup

Neutral

$12

Aug-17-18

Downgrade

Chardan Capital Markets

Buy → Neutral

$18 → $15

Oct-06-17

Resumed

Goldman

Neutral

Jul-29-21 03:05PM	Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-27-21 07:00AM	Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021 GlobeNewswire
Jul-06-21 10:06AM	Here is What Hedge Funds Think About Amicus Therapeutics, Inc. (FOLD) Insider Monkey
Jun-22-21 07:21AM	Intuit Launches New Accelerator for AI-focused Startups to Help Communities Overcome Financial Challenges in North America Business Wire
06:00AM	America's SBDC Collaborates with Coalition of Small Business Providers for "Launchpad America" to Help Entrepreneurs, Startups Succeed as Nation Emerges from Pandemic PR Newswire
Jun-14-21 07:00AM	Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors GlobeNewswire
Jun-09-21 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report? Zacks
Jun-08-21 07:00AM	Amicus Therapeutics Announces United Kingdoms MHRA Grants Early Access to AT-GAA GlobeNewswire
Jun-03-21 06:48AM	Increases to Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Compensation Might Cool off for now Simply Wall St.
May-29-21 04:00AM	Insider Buying: The Amicus Therapeutics, Inc. (NASDAQ:FOLD) Independent Director Just Bought 274% More Shares Simply Wall St.
May-28-21 07:00AM	Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference GlobeNewswire
May-21-21 07:00AM	Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases GlobeNewswire
May-11-21 11:55AM	Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y Zacks
May-10-21 06:30PM	Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript Motley Fool
09:05AM	Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates GlobeNewswire
06:45AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-07-21 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021 GlobeNewswire
May-06-21 07:00AM	Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development GlobeNewswire
May-05-21 01:21PM	Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy? Insider Monkey
07:00AM	Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting GlobeNewswire
May-03-21 03:01PM	Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
08:30AM	Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease Benzinga
07:00AM	Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease GlobeNewswire
Apr-28-21 07:00AM	Amicus Therapeutics Recognized as a Great Place to Work® in Europe GlobeNewswire
Apr-26-21 07:00AM	Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021 GlobeNewswire
Apr-18-21 05:40AM	Is Amicus Therapeutics (NASDAQ:FOLD) Using Debt Sensibly? Simply Wall St.
Apr-14-21 12:33PM	Why Amicus Therapeutics Stock Is Soaring Today Motley Fool +7.20%
Apr-08-21 10:47AM	Is FOLD Stock A Buy or Sell? Insider Monkey
Mar-15-21 07:00AM	Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference GlobeNewswire
Mar-02-21 12:51PM	Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold Zacks -5.26%
01:30AM	Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript Motley Fool
Mar-01-21 08:35AM	Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:24AM	Amicus Therapeutics: Q4 Earnings Insights Benzinga
07:00AM	Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates GlobeNewswire
06:30AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-21 10:10AM	Earnings Preview for Amicus Therapeutics Benzinga
Feb-18-21 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-17-21 07:00AM	Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021 GlobeNewswire
Feb-12-21 04:22PM	Why This Rare-Disease Biotech Stock Just Lost A Third Of Its Value Investor's Business Daily -32.89%
10:06AM	Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021 Benzinga
07:55AM	SVB Leerink, J.P. Morgan downgrade Amicus stock after Phase 3 data for rare disease drug comes out MarketWatch
07:19AM	Amicus Reports Disappointing Tests Results for Pompe Disease Drug TheStreet.com
Feb-11-21 04:01PM	Amicus AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study GlobeNewswire
Feb-08-21 02:30PM	Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium 2021 GlobeNewswire
02:30PM	Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium 2021 GlobeNewswire
Jan-28-21 08:40AM	Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options Zacks
Jan-21-21 07:00AM	Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium 2021 GlobeNewswire
Jan-18-21 02:37AM	If You Had Bought Amicus Therapeutics (NASDAQ:FOLD) Stock Five Years Ago, You Could Pocket A 191% Gain Today Simply Wall St.
Jan-11-21 07:00AM	Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook GlobeNewswire
Jan-05-21 07:00AM	Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-20 11:36AM	Is FOLD A Good Stock To Buy Now? Insider Monkey
Dec-18-20 02:00PM	Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst Benzinga
Dec-15-20 08:42AM	Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.1% Zacks
Dec-13-20 03:16AM	A Look At The Intrinsic Value Of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Simply Wall St.
Dec-07-20 07:00AM	Amicus Therapeutics Named a Great Place to Work-Certified Company in 2020 GlobeNewswire
Dec-05-20 11:32AM	Why Is Amicus Therapeutics (FOLD) Up 8.6% Since Last Earnings Report? Zacks
Dec-02-20 03:52PM	Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA Zacks
07:00AM	Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors GlobeNewswire
Dec-01-20 07:00AM	Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease GlobeNewswire
Nov-23-20 07:00AM	Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire
Nov-19-20 09:16AM	Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag Zacks
Nov-07-20 09:29AM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported And Analysts Have Been Lifting Their Price Targets Simply Wall St.
Nov-06-20 06:30PM	Amicus Therapeutics Inc (FOLD) Q3 2020 Earnings Call Transcript Motley Fool
10:52AM	Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat Zacks
Nov-05-20 09:15AM	Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates GlobeNewswire
06:30AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 07:00AM	Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference GlobeNewswire
Oct-29-20 12:34PM	Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-26-20 07:02AM	Read This Before Selling Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Simply Wall St.
Oct-22-20 07:00AM	Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire
Oct-18-20 08:31AM	3 Monster Growth Stocks That Could Reach New Highs TipRanks
Oct-12-20 08:22AM	4 Breakout Stocks for Explosive Returns Zacks
07:00AM	Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society GlobeNewswire
Sep-24-20 07:00AM	Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy GlobeNewswire
Sep-15-20 09:07AM	Is Amicus Therapeutics, Inc. (FOLD) Going to Burn These Hedge Funds? Insider Monkey
Sep-09-20 11:30AM	Amicus Therapeutics (FOLD) Down 7.5% Since Last Earnings Report: Can It Rebound? Zacks
Sep-04-20 06:37AM	How Does Amicus Therapeutics' (NASDAQ:FOLD) CEO Pay Compare With Company Performance? Simply Wall St.
Sep-03-20 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020 GlobeNewswire -5.05%
Aug-10-20 07:01PM	Amicus Therapeutics Inc (FOLD) Q2 2020 Earnings Call Transcript Motley Fool
08:25AM	Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:27AM	Recap: Amicus Therapeutics Q2 Earnings Benzinga
07:00AM	Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates GlobeNewswire
Aug-04-20 07:00AM	Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference GlobeNewswire
Aug-03-20 12:31PM	Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-31-20 07:42AM	New Strong Sell Stocks for July 31st Zacks
Jul-28-20 07:00AM	Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020 GlobeNewswire
Jul-17-20 08:04AM	The Amicus Therapeutics (NASDAQ:FOLD) Share Price Has Gained 16% And Shareholders Are Hoping For More Simply Wall St.
07:32AM	Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing GlobeNewswire
Jul-12-20 08:16PM	Did Hedge Funds Make The Right Call On Amicus Therapeutics, Inc. (FOLD)? Insider Monkey
Jun-22-20 09:23AM	Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9% Zacks
Jun-08-20 03:38AM	Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands Insider Monkey -9.00%
Jun-06-20 11:31AM	Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report? Zacks
Jun-04-20 07:00AM	Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
May-21-20 02:25PM	Edited Transcript of FOLD earnings conference call or presentation 7-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-19-20 09:47AM	Billionaire Steven Cohen Bets Big on These 3 Stocks TipRanks
May-10-20 09:50AM	Analysts Are Updating Their Amicus Therapeutics, Inc. (NASDAQ:FOLD) Estimates After Its First-Quarter Results Simply Wall St.
May-09-20 01:31PM	Amicus Therapeutics Inc (FOLD) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crowley John F	Chairman & CEO	Jul 12	Sale	9.31	14,885	138,652	862,345	Jul 14 09:08 PM
WHITMAN BURKE W	Director	Jul 01	Buy	9.60	1,500	14,400	59,082	Jul 14 09:09 PM
Crowley John F	Chairman & CEO	Jun 15	Option Exercise	4.38	22,000	96,360	899,230	Jun 17 08:06 PM
Crowley John F	Chairman & CEO	Jun 15	Sale	10.26	22,000	225,632	877,230	Jun 17 08:06 PM
Campbell Bradley L	Chief Operating Officer	Jun 07	Option Exercise	3.21	73,110	234,659	474,618	Jun 09 07:30 PM
Crowley John F	Chairman & CEO	Jun 07	Option Exercise	6.31	22,000	138,913	906,730	Jun 09 07:31 PM
Campbell Bradley L	Chief Operating Officer	Jun 07	Sale	10.01	10,514	105,207	457,268	Jun 09 07:30 PM
Crowley John F	Chairman & CEO	Jun 07	Sale	10.01	29,500	295,192	877,230	Jun 09 07:31 PM
WHITMAN BURKE W	Director	Jun 01	Buy	9.24	1,500	13,861	47,467	Jun 02 06:26 PM
Bleil Lynn Dorsey	Director	May 25	Buy	8.74	28,605	250,008	50,310	May 27 04:16 PM
RAAB MICHAEL	Director	May 18	Option Exercise	7.56	5,634	42,593	26,634	May 20 05:03 PM
Campbell Bradley L	Chief Operating Officer	May 03	Option Exercise	6.45	10,514	67,815	422,536	May 05 05:59 PM
MCGLYNN MARGARET G	Director	May 03	Option Exercise	7.51	10,000	75,100	37,919	May 05 06:01 PM
WHITMAN BURKE W	Director	May 03	Buy	10.21	1,500	15,315	45,967	May 05 06:00 PM
Crowley John F	Chairman & CEO	May 03	Sale	10.28	7,500	77,089	884,730	May 05 05:59 PM
Campbell Bradley L	Chief Operating Officer	May 03	Sale	10.27	10,514	107,970	412,022	May 05 05:59 PM
MCGLYNN MARGARET G	Director	May 03	Sale	10.27	10,000	102,704	27,919	May 05 06:01 PM
Crowley John F	Chairman & CEO	Apr 22	Sale	10.01	7,683	76,898	892,230	Apr 26 05:37 PM
Crowley John F	Chairman & CEO	Apr 15	Option Exercise	6.45	22,000	141,900	921,913	Apr 19 07:21 PM
Crowley John F	Chairman & CEO	Apr 15	Sale	10.09	22,000	222,086	899,913	Apr 19 07:21 PM
Campbell Bradley L	Chief Operating Officer	Apr 01	Option Exercise	6.45	10,514	67,815	389,371	Apr 05 06:19 PM
WHITMAN BURKE W	Director	Apr 01	Buy	10.00	1,500	15,000	44,467	Apr 05 06:15 PM
Crowley John F	Chairman & CEO	Apr 01	Sale	10.00	7,500	75,000	821,524	Apr 05 06:17 PM
Campbell Bradley L	Chief Operating Officer	Apr 01	Sale	10.03	10,514	105,505	378,857	Apr 05 06:19 PM
Crowley John F	Chairman & CEO	Mar 22	Sale	10.29	7,682	79,061	829,024	Mar 24 05:11 PM
Crowley John F	Chairman & CEO	Mar 15	Option Exercise	6.45	22,000	141,900	858,706	Mar 17 07:11 PM
Crowley John F	Chairman & CEO	Mar 15	Sale	10.77	22,000	236,988	836,706	Mar 17 07:11 PM
Quimi Daphne	Chief Financial Officer	Mar 05	Option Exercise	2.94	16,628	48,886	275,998	Mar 09 05:38 PM
Campbell Bradley L	Chief Operating Officer	Mar 01	Option Exercise	6.45	10,514	67,815	389,371	Mar 03 07:03 PM
WHITMAN BURKE W	Director	Mar 01	Buy	12.40	1,500	18,600	42,967	Mar 03 06:58 PM
Crowley John F	Chairman & CEO	Mar 01	Sale	11.85	7,500	88,881	836,706	Mar 03 07:04 PM
Campbell Bradley L	Chief Operating Officer	Mar 01	Sale	11.84	10,514	124,516	378,857	Mar 03 07:03 PM
Crowley John F	Chairman & CEO	Feb 22	Sale	11.98	7,682	92,027	844,206	Feb 24 05:07 PM
Crowley John F	Chairman & CEO	Feb 16	Option Exercise	6.45	22,000	141,900	873,888	Feb 18 06:48 PM
Crowley John F	Chairman & CEO	Feb 16	Sale	12.26	22,000	269,700	851,888	Feb 18 06:48 PM
Campbell Bradley L	Chief Operating Officer	Feb 01	Option Exercise	6.45	10,514	67,815	389,371	Feb 03 05:58 PM
WHITMAN BURKE W	Director	Feb 01	Buy	19.09	1,500	28,637	41,467	Feb 03 06:00 PM
Crowley John F	Chairman & CEO	Feb 01	Sale	19.08	7,500	143,077	851,888	Feb 03 05:59 PM
Campbell Bradley L	Chief Operating Officer	Feb 01	Sale	19.08	10,514	200,571	378,857	Feb 03 05:58 PM
Crowley John F	Chairman & CEO	Jan 20	Sale	21.51	50,000	1,075,325	859,388	Jan 20 06:14 PM
Crowley John F	Chairman & CEO	Jan 15	Option Exercise	6.45	22,000	141,900	931,388	Jan 20 06:14 PM
Crowley John F	Chairman & CEO	Jan 15	Sale	22.24	22,000	489,368	909,388	Jan 20 06:14 PM
Campbell Bradley L	Chief Operating Officer	Jan 04	Option Exercise	6.45	10,514	67,815	316,847	Jan 05 07:40 PM
WHITMAN BURKE W	Director	Jan 04	Buy	23.17	1,500	34,755	39,967	Jan 05 07:31 PM
Crowley John F	Chairman & CEO	Jan 04	Sale	22.17	7,500	166,305	745,429	Jan 05 08:07 PM
Campbell Bradley L	Chief Operating Officer	Jan 04	Sale	22.17	10,514	233,125	306,333	Jan 05 07:40 PM
Quimi Daphne	Chief Financial Officer	Dec 21	Option Exercise	2.94	5,000	14,700	249,344	Dec 23 05:45 PM
Quimi Daphne	Chief Financial Officer	Dec 21	Sale	24.09	5,000	120,474	244,344	Dec 23 05:45 PM
Quimi Daphne	Chief Financial Officer	Dec 15	Option Exercise	3.27	30,321	99,222	248,500	Dec 17 04:32 PM
Campbell Bradley L	Chief Operating Officer	Dec 15	Option Exercise	5.45	20,828	113,597	359,592	Dec 17 04:31 PM
Crowley John F	Chairman & CEO	Dec 15	Option Exercise	6.45	22,000	141,900	845,513	Dec 16 05:16 PM
Crowley John F	Chairman & CEO	Dec 15	Sale	23.91	22,000	526,101	823,513	Dec 16 05:16 PM
Do Hung	Chief Science Officer	Dec 14	Sale	23.88	111,125	2,653,276	409,682	Dec 16 05:15 PM
Campbell Bradley L	Chief Operating Officer	Dec 01	Option Exercise	2.52	24,783	62,453	363,547	Dec 02 06:39 PM
WHITMAN BURKE W	Director	Dec 01	Buy	23.50	1,500	35,250	38,467	Dec 03 06:27 PM
Crowley John F	Chairman & CEO	Dec 01	Sale	22.77	7,500	170,776	823,513	Dec 02 06:41 PM
Campbell Bradley L	Chief Operating Officer	Dec 01	Sale	22.77	24,783	564,192	338,764	Dec 02 06:39 PM
Prout Samantha	Principal Accounting Officer	Nov 04	Option Exercise	14.40	5,931	85,378	23,066	Nov 06 05:57 PM
Prout Samantha	Principal Accounting Officer	Nov 04	Sale	20.00	5,931	118,620	17,135	Nov 06 05:57 PM
Crowley John F	Chairman & CEO	Nov 02	Option Exercise	5.96	23,975	142,891	864,888	Nov 04 07:24 PM
Campbell Bradley L	Chief Operating Officer	Nov 02	Option Exercise	2.52	24,782	62,451	363,546	Nov 04 07:11 PM
WHITMAN BURKE W	Director	Nov 02	Buy	18.01	1,500	27,015	36,967	Nov 04 07:25 PM
Crowley John F	Chairman & CEO	Nov 02	Sale	17.87	33,875	605,272	831,013	Nov 04 07:24 PM
Campbell Bradley L	Chief Operating Officer	Nov 02	Sale	17.87	24,782	442,792	338,764	Nov 04 07:11 PM
Do Hung	Chief Science Officer	Oct 09	Option Exercise	10.19	193,700	1,974,507	714,507	Oct 13 05:00 PM
Do Hung	Chief Science Officer	Oct 09	Sale	15.03	193,700	2,911,272	520,807	Oct 13 05:00 PM
Quimi Daphne	Chief Financial Officer	Oct 02	Option Exercise	2.45	11,000	26,950	218,179	Oct 05 05:10 PM
Crowley John F	Chairman & CEO	Oct 01	Option Exercise	5.96	20,000	119,200	870,813	Oct 05 05:11 PM
Quimi Daphne	Chief Financial Officer	Oct 01	Option Exercise	2.94	5,000	14,700	212,179	Oct 05 05:10 PM
WHITMAN BURKE W	Director	Oct 01	Buy	14.28	1,500	21,413	35,467	Oct 05 05:12 PM
Crowley John F	Chairman & CEO	Oct 01	Sale	14.02	29,900	419,105	840,913	Oct 05 05:11 PM
Quimi Daphne	Chief Financial Officer	Oct 01	Sale	14.02	5,000	70,099	207,179	Oct 05 05:10 PM
Barth Jay	Chief Medical Officer	Sep 30	Option Exercise	2.29	4,064	9,307	167,268	Oct 02 04:34 PM
Barth Jay	Chief Medical Officer	Sep 30	Sale	14.51	4,064	58,951	163,204	Oct 02 04:34 PM
Campbell Bradley L	Chief Operating Officer	Sep 28	Option Exercise	2.52	24,782	62,451	363,546	Sep 30 04:38 PM
Campbell Bradley L	Chief Operating Officer	Sep 28	Sale	13.89	24,782	344,205	338,764	Sep 30 04:38 PM
Crowley John F	Chairman & CEO	Sep 01	Option Exercise	5.96	20,000	119,200	880,713	Sep 02 04:28 PM
WHITMAN BURKE W	Director	Sep 01	Buy	14.62	1,500	21,930	33,967	Sep 02 04:28 PM
Crowley John F	Chairman & CEO	Sep 01	Sale	14.18	29,900	423,850	850,813	Sep 02 04:28 PM
Barth Jay	Chief Medical Officer	Aug 31	Option Exercise	6.10	28,750	175,375	191,954	Sep 02 04:27 PM
Barth Jay	Chief Medical Officer	Aug 31	Sale	14.74	28,750	423,746	163,204	Sep 02 04:27 PM
Crowley John F	Chairman & CEO	Aug 17	Option Exercise	5.13	20,000	102,600	880,713	Aug 19 04:56 PM
Crowley John F	Chairman & CEO	Aug 17	Sale	14.89	20,000	297,814	860,713	Aug 19 04:56 PM
Prout Samantha	Principal Accounting Officer	Aug 05	Option Exercise	10.04	198	1,988	17,333	Aug 07 08:04 PM
Prout Samantha	Principal Accounting Officer	Aug 05	Sale	15.05	198	2,980	17,135	Aug 07 08:04 PM
Crowley John F	Chairman & CEO	Aug 03	Option Exercise	5.96	20,000	119,200	900,368	Aug 05 04:02 PM
Campbell Bradley L	Chief Operating Officer	Aug 03	Option Exercise	6.06	10,000	60,600	348,764	Aug 05 04:03 PM
WHITMAN BURKE W	Director	Aug 03	Buy	14.53	1,500	21,795	32,467	Aug 05 04:05 PM
Campbell Bradley L	Chief Operating Officer	Aug 03	Sale	14.78	10,000	147,779	338,764	Aug 05 04:03 PM
Crowley John F	Chairman & CEO	Aug 03	Sale	14.78	39,655	586,081	860,713	Aug 05 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience